Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PERK Lentiviral Activation Particles (h): sc-400080-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- PERK Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- PERK Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by PERK Lentiviral Activation Plasmid (h) and PERK Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the EIF2AK3 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: PERK Antibody (B-5): sc-377400
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PERK Lentiviral Activation Particles (h) | sc-400080-LAC | 200 µl | $455.00 |
Human EIF2AK3 encodes PERK, an ER-resident transmembrane kinase that functions as a primary sensor of endoplasmic reticulum stress in the unfolded protein response. Upon activation, PERK phosphorylates eIF2α to attenuate global translation while promoting selective translation of stress-responsive transcripts such as ATF4, thereby coordinating redox balance, amino acid metabolism, and autophagy programs. PERK signaling interfaces with proteostasis, mitochondrial function, and inflammatory pathways, shaping cell fate decisions between adaptation and apoptosis during prolonged stress. Dysregulated EIF2AK3/PERK activity has been implicated in disorders characterized by chronic ER stress, including neurodegeneration, metabolic dysfunction, and tumor microenvironment adaptation, making it a key node for mechanistic studies of stress signaling.
PERK Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient EIF2AK3 upregulation across a broader range of human cell types.
PERK Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the EIF2AK3 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous PERK expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native EIF2AK3 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.